BDTX
Black Diamond Therapeutics Inc

2,662
Loading...
Loading...
News
all
press releases
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.
Zacks·8d ago
News Placeholder
More News
News Placeholder
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
Zacks·10d ago
News Placeholder
Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?
Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
Zacks·11d ago
News Placeholder
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.
Zacks·21d ago
News Placeholder
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.
Zacks·28d ago
News Placeholder
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.
Zacks·29d ago
News Placeholder
Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why
Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High
As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.
Stocktwits·7mo ago
News Placeholder
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows...
Benzinga·1y ago

Latest BDTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.